TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
EMPOWER YOURSELF WITH KNOWLEDGE
By Seth Haddix, PhD | EHE Biobank Coordinator When patients are thinking about surgery, a new biopsy, or other procedure, their minds are filled with decisions and worry. Tissue donation isn’t usually top of mind, and for more common cancers, it is not something we think about as a priority. For an ultra-rare cancer like […]
Read MoreThe 9th Annual YAP/TAZ and TEADs: At the Crossroads of Cancer workshop took place June 9-13, 2025, in the stunning mountain town of Telluride, Colorado. Hosted by the Telluride Science and Innovation Center and organized by Drs. Guy Weinberg and John Lamar, this unique gathering brought together top-tier researchers and clinicians from academia and industry […]
Read MoreThe EHE Foundation is proud to support the next generation of scientists working to unlock the mysteries of epithelioid hemangioendothelioma (EHE). Recognizing the importance of academic and scientific conferences, the Foundation provides annual support to help young investigators overcome financial barriers that might otherwise prevent them from attending these crucial events. A 2025 Fellowship Travel […]
Read MoreThis Spring, the EHE community showed up stronger than ever for the 2025 EHE Fun Run & Walk, raising an astounding $90,000+ to fund research aimed at improving outcomes in epithelioid hemangioendothelioma (EHE). This marks a record-breaking year for our signature awareness and fundraising event! Each year, the Fun Run & Walk brings together patients, […]
Read MoreJoin The EHE Foundation’s Director of Research, Denise Robinson, as she explains the power of patients to advance research into EHE. What is patient-powered research, why does it matter, and how can you contribute? Join us to learn what’s happening in EHE research and the pivotal role you play in advancing our understanding of this […]
Read MoreIkena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]
Read MoreThank you! Together, we raised more than $160,000 to fund critically needed research into epithelioid hemangioendothelioma (EHE). Rare cancers, like EHE, lack sufficient governmental and pharmaceutical funding sources available for more common cancers. Your donations support our work to level the playing field. A special thanks to: Thank you for joining us in our fight […]
Read More